Loading...
ALMS
XNAS
Market cap514mUSD
Nov 20, Last price  
3.96USD
1D
-8.55%
1Q
-83.62%
IPO
-68.42%
Name

Alumis Inc

Chart & performance

D1W1MN
XNAS:ALMS chart
P/E
—
P/S
21.38
EPS
—
Vol. 1Y
133.51%
Shs. 5Y
—
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
24m
00024,050,000
Net income
-243m
L-17.30%
-111,930,000-154,993,000-294,233,000-243,325,000
CFO
-370m
L+44.87%
-107,722,000-129,975,000-255,078,000-369,523,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Key people

Chairman of the Board, President, Chief Executive Officer · since 2021
Chief Financial Officer · since 2022
Chief Scientific Officer · since 2021
Derrick Richardson
Senior Vice President - People and Culture · since 2023
Mark Bradley
Chief Development Officer · since 2021
Jorn Drappa
Chief Medical Officer, Head - Research and Development · since 2022
Chief Business and Strategy Officer · since 2025
Sara Klein
Chief Legal Officer and Corporate Secretary · since 2025
Director · since 2022
Director · since 2022
James Tananbaum
Director · since 2021
Director · since 2021
Independent Director · since 2024
Independent Director · since 2024
Independent Director · since 2025
IPO date
Jun 28, 2024
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFY
2025‑122024‑122023‑122022‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT